Literature DB >> 11320032

Proliferative activity and p53 expression in primary and recurrent pterygia.

I Chowers1, J Pe'er, E Zamir, N Livni, M Ilsar, J Frucht-Pery.   

Abstract

PURPOSE: To assess p53 expression and proliferative activity in primary and recurrent pterygia from the same eyes.
DESIGN: Retrospective comparative human tissue study. PARTICIPANTS: Tissue from excised primary pterygia that did not recur (group A, n = 10) was compared with tissue from primary pterygia that recurred (group B, n = 10) and to the recurrent pterygia tissue that was excised from subjects in group B (group C, n = 10). Ten normal conjunctivas served as controls (group D).
METHODS: Sections from each pterygium were immunostained with the MIB-1 and bp53. 12 monoclonal antibodies that react with Ki-67 and p53 antigens, respectively. MAIN OUTCOME MEASURES: Proliferative activity was calculated as the mean of the MIB-1 positive cell count per eyepiece grid in high magnification (x40) (positive cell count/grid). Percentage of positive cells of all cells in the grid area was evaluated in the p53-stained sections.
RESULTS: Proliferative activity was found in the epithelium overlying the pterygia and normal conjunctiva. The mean MIB-1 positive cell count/grid +/- standard error was 2.84 +/- 1.07, 1.74 +/- 0.82, 3.83 +/- 1.35, and 0.86 +/- 0.33 in groups A, B, C, and D, respectively (P = 0.17, Kruskal-Wallis). P53 staining was found in 50% of pterygia in groups A, B, and C; none of the normal conjunctival tissues showed p53 immunoreactivity. Four of five p53-positive tissues in group B were p53-negative in group C. In the p53-positive pterygia, less than 10% of cells were p53 positive. However, p53-positive pterygia had higher mean MIB-1 positive cell count/grid +/- standard error as compared with the p53-negative lesions, 4.56 +/- 0.94 vs 1.39 +/- 0.59 (P = 0.021, Mann-Whitney).
CONCLUSIONS: p53 immunoreactivity and high proliferative activity in the epithelium overlying the pterygium are not associated with recurrence of pterygium.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11320032     DOI: 10.1016/s0161-6420(00)00651-5

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  22 in total

1.  Survivin and p53 expression in primary and recurrent pterygium in Chinese patients.

Authors:  Li-Wei Zhang; Bai-Hua Chen; Xing-Hua Xi; Qian-Qian Han; Luo-Sheng Tang
Journal:  Int J Ophthalmol       Date:  2011-08-18       Impact factor: 1.779

2.  Increased expression of nestin in human pterygial epithelium.

Authors:  Dan Wen; Hua Wang; Boon Chin Heng; Hua Liu
Journal:  Int J Ophthalmol       Date:  2013-06-18       Impact factor: 1.779

3.  Current approaches and future directions in the management of pterygium.

Authors:  Kyoung Woo Kim; Jae Chan Kim
Journal:  Int J Ophthalmol       Date:  2018-05-18       Impact factor: 1.779

Review 4.  Association of human papilloma virus with pterygia and ocular-surface squamous neoplasia.

Authors:  N Di Girolamo
Journal:  Eye (Lond)       Date:  2011-12-02       Impact factor: 3.775

5.  K-ras oncogene mutation in pterygium.

Authors:  B T Ozturk; M S Yıldırım; A Zamani; B Bozkurt
Journal:  Eye (Lond)       Date:  2016-11-11       Impact factor: 3.775

6.  E-cadherin promoter hypermethylation may contribute to protein inactivation in pterygia.

Authors:  Chi-Hsien Young; Yu-Te Chiu; Tung-Sheng Shih; Wan-Ru Lin; Chun-Chi Chiang; Ying-Erh Chou; Ya-Wen Cheng; Yi-Yu Tsai
Journal:  Mol Vis       Date:  2010-06-09       Impact factor: 2.367

7.  The involvement of adult stem cells originated from bone marrow in the pathogenesis of pterygia.

Authors:  Young Soo Song; Yang Hwan Ryu; Suk Rae Choi; Jae Chan Kim
Journal:  Yonsei Med J       Date:  2005-10-31       Impact factor: 2.759

8.  An association between BPDE-like DNA adduct levels and CYP1A1 and GSTM1 polymorphisma in pterygium.

Authors:  Jai-Nien Tung; Heng-Hsiung Wu; Chun-Chi Chiang; Yi-Yu Tsai; Ming-Chih Chou; Huei Lee; Ya-Wen Cheng
Journal:  Mol Vis       Date:  2010-04-08       Impact factor: 2.367

9.  The influence of pterygium morphology on fibrin glue conjunctival autografting pterygium surgery.

Authors:  Sekelj Sandra; Janjetovic Zeljka; Vukovic Arar Zeljka; Samardzic Kristian; Aric Ivana
Journal:  Int Ophthalmol       Date:  2013-06-04       Impact factor: 2.031

10.  The use of antimetabolites as adjunctive therapy in the surgical treatment of pterygium.

Authors:  Alyaà Abood Kareem; Qasim Kadhim Farhood; Hussein Ali Alhammami
Journal:  Clin Ophthalmol       Date:  2012-11-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.